|
LE Magazine March 2003
Medications
side effects
References
1. Lazarou, J,
Pomeranz, BH, Corey, PN. Incidence of adverse drug reactions
in hospitalized patients: a meta-analysis of prospective
studies. JAMA 1998;279(15):1200-5.
2. Gilman, AG,
Rall, TW, Nies, AS, Taylor, P. Goodman and Gilman's The
Pharmacological Basis of Therapeutics. New York: Pergammon
Press, 1990 and 1996.
3. Melmon, KL,
Morrelli, HF, Hoffman, BB, Nierenberg, DW. Melmon and
Morrelli's Clinical Pharmacology: Basic Principles in
Therapeutics. (3rd Edition). New York: McGraw-Hill, Inc.,
1993.
4. American
Medical Association. AMA Drug Evaluations, Annual 1994.
Chicago: American Medical Association, 1994.
5. Grady, D. Too
Much of a Good Thing? Doctor Challenges Drug Manual. New York
Times, Oct. 12, 1999:D1-2.
6. Wernicke, JF,
Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose
fluoxetine therapy for depression. Psychopharmacology Bulletin
1988; 24(1):183-188.
7. Physicians'
Desk Reference, 57th Edition. Montvale, N.J.: Medical
Economics Company, 2003.
8. Executive
Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults.
JAMA 2001;285(19):2486-97.
9. Nowrocki, J,
Weiss, S, et al. Reduction in LDL Cholesterol by 25% to 60% in
Patients with Primary Hypercholesterolemia by Atorvastatin, a
New HMG-Co-A Reductase Inhibitor. Arteriosclerosis,
Thrombosis, and Vascular Biology 1995;15:678-682.
10.
Wolffenbuttel, BH, Mahla, G, Muller, D, et al. Efficacy and
safety of a new cholesterol synthesis inhibitor, atorvastatin,
in comparison with simvastatin and pravastatin, in subjects
with hypercholesterolemia. Netherlands Journal of Medicine
1998;52(4):131-7.
11.
Bakker-Arkema, RG, Best, J, Fayyad, R, et al. A brief review
paper of the efficacy and safety of atorvastatin in early
clinical trials. Atherosclerosis 1997;131(1):17-23.
12. Cilla, DD
Jr, Whitfield, LR, Gibson, DM, et al. Multiple-dose
pharmacokinetics, pharmacodynamics, and safety of
atorvastatin, an inhibitor of HMG-CoA reductase, in healthy
subjects. Clinical Pharmacology and Therapeutics
1996;60(6):687-95.
13. Roberts, WC.
The rule of 5 and the rule of 7 in lipid-lowering by statin
drugs. American Journal of Cardiology 1997;80:106-7.
14. Sinatra, S.
Statins: grossly overprescribed for cholesterol and
underprescribed for internal inflammation. The Sinatra Health
Report, Sept. 2002;8:1.
15.
Bristol-Myers Squibb. Advisory Committee Meeting Briefing Book
for the Rx to OTC Switch of Pravachol (Pravastatin Sodium).
Joint Meeting of Nonprescription Drugs Advisory Committee and
Endocrinologic and Metabolic Drugs Advisory Committee, FDA
website, 2000:
www.fda.gov/ohrms/dockets/ac/00/backgrd/3622b2a_part1.pdf.
16.
Nonprescription Mevacor, FDA Advisory Committee Background
Information, FDA Website, June 2000:www.fda.
gov/ohrms/dockets/ac/00/backgrd/3622b1b.pdf.
17. Ridker, PM,
Rifai, N, Rose, L, Buring, JE, Cook, Nov. R. Comparison of
C-reactive protein and low-density lipoprotein cholesterol
levels in the prediction of first cardiovascular events. New
England Journal of Medicine 2002;347:1557-1565.
18. Carroll, DN,
Roth, MT. Evidence for the cardioprotective effects of omega-3
fatty acids. Annals of Pharmacotherapy 2002;36:1950-1956.
19.
GISSI-Prevenzione Investigators: Dietary supplementation with
omega-3 polyunsaturated fatty acids and vitamin E after
myocardial infarction: results of the GISSI-Prevenzione trial.
Lancet 1999;354:447-455.
20. Elliott, WJ,
Maddy, R, Toto, R, Bakris, G. Hypertension in Patients with
Diabetes. Postgraduate Medicine 2000;107:29-38.
21. Cohen, JS.
Adverse drug effects, compliance, and the initial doses of
antihypertensive drugs recommended by the Joint National
Committee vs. the Physicians' Desk Reference. Archives of
Internal Medicine 2001;161:880-85.
22. Wolfe, MM,
Lichtenstein, DR, Singh, G. Gastrointestinal toxicity of
nonsteroidal anti-inflammatory drugs. New England Journal of
Medicine 1999;340(24):1888-99.
23. Chalmers TM.
Clinical experience with ibuprofen in the treatment of
rheumatoid arthritis. Annals of Rheumatic Diseases
1969;28:513-517.
24. Brooks CD,
Schmid FR, Biundo J, et al. Ibuprofen and aspirin in the
treatment of rheumatoid arthritis; a cooperative double-blind
trial. Rheumatology and Physical Medicine
1970;10(suppl):48-63.
25. Thompson M,
Bell D. Further experience with ibuprofen in the treatment of
arthritis. Rheumatology and Physical Medicine
1970;10(suppl):100-103.
26. Hingorani,
K. Double-blind crossover trial comparing ibuprofen with
flufenamic acid in rheumatoid arthritis. Rheumatology and
Physical Medicine 1970;10(suppl):76-82.
27. Durrigl, T,
Vitaus, M, Pucar, I, Miko, M. Diclofenac sodium (Voltaren):
Results of a multi-centre comparative trial in adult-onset
rheumatoid arthritis. Journal of International Medical
Research 1975;3:139-144.
28. Mutru O,
Penttila M, Pesonen J, Salmela P, Suhonen O, Sonck T.
Diclofenac sodium (Voltaren) and indomethacin in the
ambulatory treatment of rheumatoid arthritis: A double-blind
multicentre study. Scandinavian Journal of Rheumatology
1978;(suppl)22:51-56.
29. Ciccolunghi,
SN, Chaudri, HA, Schubiger, BI. The value and results of
long-term studies with diclofenac sodium (Voltarol).
Rheumatology and Rehabilitation 1979;(suppl2):100-115.
30. Ciccolunghi,
SN, Chaudri, HA, Schubiger, BI, Reddrop, R. Report on a
long-term tolerability study of up to two years with
diclofenac sodium (Voltaren). Scandinavian Journal of
Rheumatology 1978;(suppl)22:86-96.
31. Bensen WG,
Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis
with celecoxib: a randomized controlled trial. Mayo Clinic
Proceedings 1999;74(11):1095-105.
32. Hall, SS.
Claritin and Schering-Plough: a Prescription for Profit. New
York Times, Mar. 11, 2001:www.nytimes.com.
33. Azarbal, B,
Mirocha, J, Shah, PK, Cercek, B, Kaul, S. Adverse
Cardiovascular Events Associated with the Use of Viagra.
Journal of the American College of Cardiology
2000;35(SupplA):553A-554A. Abstract.
34. Cohen, JS.
Should Patients Be Given a Low Test Dose of sildenafil
(Viagra) Initially? Drug Safety 2000;23:1-10.
35. Digitalis:
More Is Not Necessarily Better. Journal Of The American
College Of Cardiology 1997;29:1206-13.
36. 57 Deaths in
Britain associated with Zyban. Reuters Health, Jan. 10,
2002:www.reuters.com.
37. Associated
Press. Inhaled steroids for asthma cause bone loss, study
finds. San Diego Union-Tribune, Thurs., Sept. 27,
2001:A-14.
38. Recchia, AG,
Shear, NH. Organization And Function Of An Adverse Drug
Reaction Clinic. Journal Of Clinical Psychiatry, 1994;
34:68-79.
39. Smucker, WD,
Kontak, JR. Adverse drug reactions causing hospital admission
in an elderly population: experience with a decision
algorithm. Journal of the American Board of Family Practice
1990;3(2):105-9.
40. Cheng H,
Rogers JD, Sweany AE, et al. Influence of age and gender on
the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitory activity following multiple
doses of lovastatin and simvastatin. Pharmaceutical Research
1992;9:1629-1633.
41. Williams,
RD. Medications and older adults. FDA Consumer Magazine,
Sept.-Oct. 1997.
42. Montamat,
SC, Cusack, BJ, Vestal, RE. Management of drug therapy in the
elderly. New England Journal of Medicine
1989;321(5):303-9.
43. Writing
Group for the Women's Health Initiative. Risks and Benefits of
Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA
2002;288:321-333.
44. Lacey, JV,
Mink, PJ, Lubin, JH, Sherman, ME, Troisi, R, Hartge, P, et al.
Menopausal hormone replacement therapy and risk of ovarian
cancer. JAMA 2002;288:334-341.
45. Ettinger B.
Personal perspective on low-dosage estrogen therapy for
postmenopausal women. Menopause, 1999; 6(3):273-6.
46. Weinstein L.
Efficacy of a continuous estrogen-progestin regimen in the
menopausal patient. Obstetrics and Gynecology
1987;69(6):929-32.
47. Greendale,
GA, Reboussin, BA, Hogan, P, et al. Symptom relief and side
effects of postmenopausal hormones: results from the
Postmenopausal Estrogen/Progestin Interventions Trial.
Obstetrics and Gynecology 1998;92(6):982-8.
48. McNagny, SE.
Prescribing Hormone Replacement Therapy for Menopausal
Symptoms. Annals of Internal Medicine, 1999;131:605-16.
49. Snider S.
The Pill: 30 Years of Safety Concerns. U.S. Food and Drug
Administration, Dec.
1990;www.fda.gov/bbs/topics/CONSUMER/CON00027.html. Checked:
Mar. 9, 2002.
50. Marks L.
"Not just a statistic": The history of USA and UK policy over
thrombotic disease and the oral contraceptive pill,
1960s-1970s. Social Science and Medicine
1999;49:1139-1155.
51. Vessey MP,
Inman WH. Speculations about mortality trends from venous
thromboembolic disease in England and Wales and their relation
to the pattern of oral contraceptive usage. Obstetrics and
Gynecology in the British Commonwealth 1973;80:562-566.
52. Bottiger LE,
Boman G, Eklund G, Westerholm B. Oral contraceptives and
thromboembolic disease: effects of lowering oestrogen content.
Lancet 1980;1:1097-1101.
53. Shapiro, SS,
Diem, K. The effects of ibuprofen in the treatment of
dysmenorrhea. Current Therapeutic Research
1981;30(3):327-334.
54. Wierzbicki
AS, Lumb PJ, Chik G, Crook MA. High-density lipoprotein
cholesterol and triglyceride response with simvastatin versus
atorvastatin in familial hypercholesterolemia. American
Journal of Cardiology 2000;86:547-549.
55. Ose L,
Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B.
Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in
patients with primary hypercholesterolaemia: A multinational,
randomised, double-blind study. Cerivastatin Study Group.
Current Medical Research and Opinion 1999,15:228-240.
56. Peters TK,
Muratti EN, Mehra M. Efficacy and safety of fluvastatin in
women with primary hypercholesterolaemia. Drugs.
1994;47(Suppl2):64-72.
57. Leitersdorf
E. Gender-related response to fluvastatin in patients with
heterozygous familial hypercholesterolaemia. Drugs.
1994;47(Suppl 2):54-58.
58. Lewis CE.
Characteristics and treatment of hypertension in women: a
review of the literature. American Journal of the Medical
Sciences 1996;311(4):193-9.
59. Israili, ZH,
Hall, WD. Cough and angioneurotic edema associated with
angiotensin-converting enzyme inhibitor therapy. A review of
the literature and pathophysiology. Annals of Internal
Medicine 1992;117(3):234-42.
60. Women
Sufficiently Represented in New Drug Testing, but FDA
Oversight Needs Improvement. Report to Congressional
Requesters. US General Accounting Office, GAO-01-754, July 6,
2001:www.fda.gov/womens/informat.html.
61. Exploring
the Biological Contributions to Human Health: Does Sex Matter?
Wizemann, TM, Pardue, ML, Editors, Committee on Understanding
the Biology of Sex and Gender Differences, Board on Health
Sciences Policy, Institute of Medicine, National Academy of
Sciences, National Academy Press, 2001.
62. Kritz, FL.
Mars and Venus and Drugs: Sex Differences Create Extra Risks
for Women. Washington Post, Feb. 20, 2001:T7.
63. Bowman, L.
51% Of U.S. Adults Take 2 Pills or More a Day, Survey Reports
(Scripps Howard News Service). San Diego Union-Tribune, Jan.
17, 2001:A8.
64. Zuger, A.
Caution: That dose may be too high. New York Times, September
17, 2002:nytimes.com.
65. Dorothy L.
Smith, DTC Perspectives, Jan.-Feb. 2002.
66. Reuters
Health. Medical Journals Act to Limit Drug Firms' Influence.
Reuters, Sept. 10, 2001:www.reuters.com.
67. Davidoff, F,
DeAngelis, CD, Drazen, JM, Hoey, J, Hojgaard, L, Horton, R, et
al. Sponsorship, Authorship, and Accountability. New England
Journal of Medicine, Sept. 13, 2001;345(11):825-27.
68. Schulman,
KA, Seils, DM, Timbie, JW, Sugarman, J, et al. A national
survey of provisions in clinical-trial agreements between
medical schools and industry sponsors. New England Journal of
Medicine 2002;347:1335-41.
69. Bodenheimer,
T. Uneasy Alliance -- Clinical Investigators and the
Pharmaceutical Industry. New England Journal of Medicine
2000;342:1539-44.
70. Herxheimer
A. How much drug in the tablet? Lancet 1991;337:346-8.
71. Zuger, A.
Caution: That dose may be too high. New York Times, September
17, 2002:nytimes.com.
72. Herxheimer,
A. Dosage needs systematic and critical review. BMJ
2001;323.
73. Moore, TJ,
Psaty, BM, Furberg, CD. Time to act on drug safety. JAMA
1998;279(19):1571-3.
74. Lasser, KE,
Alan, PD, Woolhandler, SJ, Himmelstein, DU, Wolfe, SM, Bor,
DH. Timing of New Black Box Warnings and Withdrawals for
Prescription Medications. JAMA 2002;287:2215-2220.
75. Gaist, D,
Jeppesen, U, Andersen, M, et al. Statins and the risk of
polyneuropathy: a case-control study. Neurology
2002;58:1333-1337.
76. Avorn, J.
The prescription as final common pathway. International
Journal of Technology Assessment in Health Care
1995:11(3):384-90).
77. Wood, AJJ,
Stein, CM, Woosley, R. Making Medicines Safer: the Need for An
Independent Drug Safety Board. New England Journal of Medicine
1998;339:1851-54.
78. Young, SA.
Is Academic Medicine for Sale? New England Journal of Medicine
2000;343:508.
79. Vollmann, J.
Gifts to physicians from the pharmaceutical industry. JAMA
2000;283:2656-8.
80. Angell, M.
Is Academic Medicine for Sale? New England Journal of Medicine
2000;342:1516-18:
81. Hensley, S.
When doctors go to class, industry often foots the bill. Wall
Street Journal, Dec. 4, 2002:A1.
82. Cimons, M.
Scientists Study Gender Gap in Drug Responses. Los Angeles
Times, Sun. June 6, 1999: A-1,8-9.
83. Angell, M,
Relman, AS. Prescription for Profit. The Washington Post, June
20, 2001:A27.
84. Cohen, JS. The One-Size Dose Does Not Fit All: Look
beyond the guidelines of drug manufacturers. Newsweek, Dec. 6,
1999:92.
85. American
Medical Association Council on Ethical and Judicial Affairs.
Code of Medical Ethics. 1998-1999 Edition. American Medical
Association, Chicago, IL.
86. Top 10 Drugs
of 2001. Pharmacy Times, Apr. 2002;68(4):10-15.
References for Table
1:
1. Clark, WG, Brater, DC, Johnson, AR.
Goth's Medical Pharmacology. 13th Edition. St. Louis: The C.V.
Mosby Company, 1992.
2. Gilman, AG, Rall, TW, Nies, AS,
Taylor, P. Goodman and Gilman's The Pharmacological Basis of
Therapeutics. New York: Pergammon Press, 1990 and 1996.
3. Martin, E.W. Hazards of Medication: A
Manual on Drug Interactions, Contraindications, and Adverse
Reactions with Other Prescribing and Drug Information. 2nd
edition. Philadelphia: J.B. Lippincott Company, 1978.
4. American Medical Association. AMA Drug
Evaluations, Annual 1994. Chicago: American Medical
Association, 1994.
5. Herxheimer, A. Dosage needs systematic
and critical review. BMJ 2001;323.
6. Heerdink, ER, Urquhart, J, Leufkens,
HG. Changes in prescribed drug doses after market
introduction. Pharmacoepidemiology and Drug Safety
2002;11:447-453.
7. Rowland, M, Sheiner, L, Steimer, J.
Variability In Drug Therapy: Description, Estimation, And
Control. A Sandoz Workshop. New York: Raven Press, New York,
1985.
References for Table
2:
1. Schatzberg AF, Dessain E, O'Neil P,
Katz DL, Cole JO. Recent studies on selective serotonergic
antidepressants: trazodone, fluoxetine, and fluvoxamine.
Journal of Clinical Psychopharmacology 1987;7(6):44S-49S.
2. Wernicke, JF,
Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose
fluoxetine therapy for depression. Psychopharmacology Bulletin
1988; 24(1):183-188.
3. Salzman C.
Practical considerations in the pharmacologic treatment of
depression in the elderly. Journal of Clinical Psychiatry
1990;59(1 Suppl):40-43.
4. Schatzberg
AF. Dosing strategies for antidepressant agents. Journal of
Clinical Psychiatry 1991:52(5suppl):14-20.
5. Cain, JW.
Poor response to fluoxetine: underlying depression,
serotonergic overstimulation, or a "therapeutic window"?
Journal of Clinical Psychiatry 1992;53(8):272-277.
6. Louie, AK,
Lewis, TB, Lannon, MD. Use of low-dose fluoxetine in major
depression and panic disorder. Journal of Clinical Psychiatry
1993;54(1):435-438.
7. Rakel, RE.
Conn's Current Therapy. Philadelphia: W.B. Saunders Company,
1993.
8. Gram, LF.
Fluoxetine-review article. New England Journal of Medicine
1994;331:1354-61.
References
for Table 5:
1. Tinkelman D, Falliers M, Bronsky
E, et al. Efficacy and safety of fexofenadine in fall seasonal
allergic rhinitis. Journal of Allergy and Clinical Immunology,
1996;97(1):1009.
2. Merlotti L, Roehrs T, Koshorek
G, Zorick F, Lamphere J, Roth T. The dose effects of zolpidem
on the sleep of healthy normals. Journal of Clinical
Psychopharmacology 1989;9:9-14.
3. Cloud, ML, Offen, WW, Matsumoto,
C. Healing and subsequent recurrence of duodenal ulcer in a
clinical trial comparing nizatidine 300-mg and 100-mg evening
doses and placebo in the treatment of active duodenal ulcer.
Current Therapeutics and Research, Clinical Experience
1989;45(3):359-367.
4. Cohen MM, Clark L, Armstrong L,
D'Souza J. Reduction of aspirin-induced fecal blood loss with
low-dose misoprostol tablets in man. Digestive Diseases and
Sciences, 1985;30(7):605-11.
5. Salkind MR, Silverstone T. A
clinical and psychometric evaluation of flurazepam. British
Journal of Clinical Pharmacology 1975;2:223-226.
6. Schatzberg AF, Dessain E, O'Neil
P, Katz DL, Cole JO. Recent studies on selective serotonergic
antidepressants: trazodone, fluoxetine, and fluvoxamine.
Journal of Clinical Psychopharmacology
1987;7:44S-49S.
7. Mendels J, Johnston R, Mattes J,
Riesenberg R. Efficacy and safety of b.i.d. doses of
venlafaxine in a dose-response study. Psychopharmacology
Bulletin 1993;29:169-174.
8. Roy, D, Dawling, S. Application
of an individually predicted dosage of amitriptyline to the
treatment of depression. International Clinical
Psychopharmacology 1987;2:307-315.
9. Ettinger, B. Personal
perspective on low-dosage estrogen therapy for postmenopausal
women. Menopause, 1999; 6(3):273-6.
10. De Aloysio, D, Rovati, LC,
Giacovelli, G, Setnikar, I, Bottiglioni, F. Efficacy on
climacteric symptoms and safety of low dose estradiol
transdermal matrix patches. Arzneimittel-Forschung
2000;50(3):293-300.
11. American Society of Hospital
Pharmacists. American Hospital Formulary Service, Drug
Information 1999. Gerald K. McEvoy, Editor. Bethesda:
1999.
12. Schatzberg AF. Dosing
strategies for antidepressant agents. Journal of Clinical
Psychiatry. 1991:52(Suppl5):14-20. Sjoqvist F, Bertilsson L. Clinical
pharmacology of antidepressant drugs: Pharmacogenetics.
Advances in Biochemistry and Psychopharmacology
1984,39:359-372.
13. Savarino, V, Mela, GS,
Zentilin, P, Bonifacino, G, Moretti, M, et al. Low bedtime
doses of H2-receptor antagonists for acute treatment of
duodenal ulcers. Digestive Diseases and Sciences
1989;34(7):1043-46.
14. Lauritsen, K, Andersen, BN,
Laursen, LS, Hansen, J, Havelund, T, Eriksen, J, et al.
Omeprazole 20 mg three days a week and 10 mg daily in
prevention of duodenal ulcer relapse; double-blind comparative
trial. Gastroenterology 1991;100(3):663-9.
15. Rainer, MK, Masching, AJ, Ertl,
MG, Kraxberger, E, Haushofer, M. Effect of risperidone on
behavioral and psychological symptoms and cognitive function
in dementia. Journal of Clinical Psychiatry
2001;62:894-900.
16. Elliott RL, Shillcutt SD. Using
newer antidepressants in the medically ill: An update. Primary
Psychiatry. 1996;3:42-56.
17. Rickels K, Schweizer E, Clary
C, Fox I, Weise C. Nefazodone and imipramine in major
depression: A placebo-controlled trial. British Journal of
Psychiatry. 1994;164:802-805.
18. McCue R. Using tricyclic
antidepressants in the elderly. Clinical Geriatric Medicine
1992;8:323-334.
19. Preskorn S. Pharmacokinetics of
antidepressants: Why and how they are relevant to treatment.
Journal of Clinical Psychiatry. 1993;54(suppl
9):14-34.
20. The Fifth Report of the Joint
National Committee on Detection, Evaluation, and Treatment of
High Blood Pressure (JNC V). Archives of Internal Medicine
1993;153:154-183.
21. Kirksey DF, Harto-Truax N.
Private practice evaluation of the safety and efficacy of
bupropion in depressed outpatients. Journal of Clinical
Psychiatry. 1983;44:143-147.
22. Rossner S; Sjostrom L; Noack R;
Meinders AE; Noseda G. Weight loss, weight maintenance, and
improved cardiovascular risk factors after 2 years treatment
with orlistat for obesity. European Orlistat Obesity Study
Group. Obesity Research 2000;8:49-61.52.
23. Dobrilla, G, Barbara, L,
Bianchi-Porro, G, Felder, M, Mazzacca, G, et al. Placebo
Controlled Studies with Ranitidine in Duodenal Ulcer.
Scandinavian Journal of Gastroenterology
1981;69(suppl):103-4.
24. Steinhagen-Thiessen E.
Comparative efficacy and tolerability of 5 and 10 mg
simvastatin and 10 mg pravastatin in moderate primary
hypercholesterolemia. Simvastatin Pravastatin European Study
Group. Cardiology, 1994, 85(3-4):244-54.
25. Tuomilehto J; Guimaraes AC;
Kettner H; Lithell H; Pitkanen M; et al. Dose-response of
simvastatin in primary hypercholesterolemia. Journal of
Cardiovascular Pharmacology, 1994; 24(6):941-9.
26. Beck TM, Ciociola AA, Jones SE,
et al. Efficacy of oral ondansetron in the prevention of
emesis in outpatients receiving cyclophosphamide-based
chemotherapy. Annals of Internal Medicine
1993;118:407-413.
References for Table
6:
1. Rochon, PA, Anderson, GM, Tu,
JV, et al. Age- and gender-related use of low-dose drug
therapy: the need to manufacture low-dose therapy and evaluate
the minimum effective dose. Journal of the American Geriatrics
Society, 1999 47(8):954-9.
2. Clark, WG, Brater, DC, Johnson,
AR. Goth's Medical Pharmacology. 13th Edition. St. Louis: The
C.V. Mosby Company, 1992.
3. Wolfe, SM, Hope, RE. Worst
Pills, Best Pills II: The Older Adult's Guide to Avoiding
Drug-Induced Death or Illness. Washington, D.C.: Public
Citizen's Health Research Group, 1993.
4. Brawn, LA, Castleden, CM.
Adverse drug reactions. An overview of special considerations
in the management of the elderly patient. Drug Safety
1990;5(6):421-35.
5. Williams, RD. Medications and
older adults. FDA Consumer Magazine, Sept.-Oct.
1997.
6. Everitt, DE, Avorn, J. Drug
prescribing for the elderly. Archives of Internal Medicine
1986;146(12):2393-6.
7. Rochon, PA, Gurwitz, JH.
Optimising drug treatment for elderly people: the prescribing
cascade. BMJ 1997;315(7115):1096-9.
8. United States Pharmacopeia, Drug
Information (USP DI): Drug Information for the Health Care
Professional. Taunton, MA: Rand McNally, 1994.
9. Gibian T. Rational drug therapy
in the elderly, or, how not to poison your elderly patients.
Australian Family Physician 1992;21(12):1755-60.
Back to
the Magazine Forum
|